Last reviewed · How we verify

Fludarabine, OKT3, Treosulfan, Thiotepa

St. Anna Kinderkrebsforschung · Phase 3 active Small molecule

Fludarabine, OKT3, Treosulfan, Thiotepa is a Multi-agent conditioning regimen (purine analog, monoclonal antibody, alkylating agents) Small molecule drug developed by St. Anna Kinderkrebsforschung. It is currently in Phase 3 development for Conditioning regimen prior to hematopoietic stem cell transplantation in pediatric leukemia and lymphoma. Also known as: ATG:Antithymoglobuline, ATG: Antithymoglobuline.

This is a multi-drug conditioning regimen combining purine analog, T-cell depleting monoclonal antibody, and alkylating agents to suppress the immune system and ablate bone marrow prior to hematopoietic stem cell transplantation.

This is a multi-drug conditioning regimen combining purine analog, T-cell depleting monoclonal antibody, and alkylating agents to suppress the immune system and ablate bone marrow prior to hematopoietic stem cell transplantation. Used for Conditioning regimen prior to hematopoietic stem cell transplantation in pediatric leukemia and lymphoma.

At a glance

Generic nameFludarabine, OKT3, Treosulfan, Thiotepa
Also known asATG:Antithymoglobuline, ATG: Antithymoglobuline
SponsorSt. Anna Kinderkrebsforschung
Drug classMulti-agent conditioning regimen (purine analog, monoclonal antibody, alkylating agents)
TargetdTMP synthase (fludarabine); CD3 (OKT3); DNA (treosulfan, thiotepa)
ModalitySmall molecule
Therapeutic areaOncology / Hematology
PhasePhase 3

Mechanism of action

Fludarabine is a purine analog that inhibits DNA synthesis in lymphocytes; OKT3 is a monoclonal antibody targeting CD3 on T cells for immune depletion; Treosulfan and Thiotepa are alkylating agents that cause DNA crosslinking and cell death. Together, this regimen provides myeloablation and immunosuppression to prepare patients for stem cell transplantation and reduce graft rejection and leukemic relapse.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fludarabine, OKT3, Treosulfan, Thiotepa

What is Fludarabine, OKT3, Treosulfan, Thiotepa?

Fludarabine, OKT3, Treosulfan, Thiotepa is a Multi-agent conditioning regimen (purine analog, monoclonal antibody, alkylating agents) drug developed by St. Anna Kinderkrebsforschung, indicated for Conditioning regimen prior to hematopoietic stem cell transplantation in pediatric leukemia and lymphoma.

How does Fludarabine, OKT3, Treosulfan, Thiotepa work?

This is a multi-drug conditioning regimen combining purine analog, T-cell depleting monoclonal antibody, and alkylating agents to suppress the immune system and ablate bone marrow prior to hematopoietic stem cell transplantation.

What is Fludarabine, OKT3, Treosulfan, Thiotepa used for?

Fludarabine, OKT3, Treosulfan, Thiotepa is indicated for Conditioning regimen prior to hematopoietic stem cell transplantation in pediatric leukemia and lymphoma.

Who makes Fludarabine, OKT3, Treosulfan, Thiotepa?

Fludarabine, OKT3, Treosulfan, Thiotepa is developed by St. Anna Kinderkrebsforschung (see full St. Anna Kinderkrebsforschung pipeline at /company/st-anna-kinderkrebsforschung).

Is Fludarabine, OKT3, Treosulfan, Thiotepa also known as anything else?

Fludarabine, OKT3, Treosulfan, Thiotepa is also known as ATG:Antithymoglobuline, ATG: Antithymoglobuline.

What drug class is Fludarabine, OKT3, Treosulfan, Thiotepa in?

Fludarabine, OKT3, Treosulfan, Thiotepa belongs to the Multi-agent conditioning regimen (purine analog, monoclonal antibody, alkylating agents) class. See all Multi-agent conditioning regimen (purine analog, monoclonal antibody, alkylating agents) drugs at /class/multi-agent-conditioning-regimen-purine-analog-monoclonal-antibody-alkylating-agents.

What development phase is Fludarabine, OKT3, Treosulfan, Thiotepa in?

Fludarabine, OKT3, Treosulfan, Thiotepa is in Phase 3.

What are the side effects of Fludarabine, OKT3, Treosulfan, Thiotepa?

Common side effects of Fludarabine, OKT3, Treosulfan, Thiotepa include Myelosuppression / neutropenia, Infection, Mucositis, Nausea and vomiting, Hepatotoxicity, Graft-versus-host disease.

What does Fludarabine, OKT3, Treosulfan, Thiotepa target?

Fludarabine, OKT3, Treosulfan, Thiotepa targets dTMP synthase (fludarabine); CD3 (OKT3); DNA (treosulfan, thiotepa) and is a Multi-agent conditioning regimen (purine analog, monoclonal antibody, alkylating agents).

Related